Cannabis Law Report

JULY 22, 2021

As regulations develop, the next phase of the Company’s strategy will involve the inclusion of alternative and psychedelic therapies into Levitee’s platform of traditional healthcare assets. The company’s current portfolio of assets includes Sporeo Supply and MONKE Nutraceuticals.

eCommerce 105

eCommerce Therapy Media Access 105

The Cannigma

JULY 17, 2022

You don’t need a medical condition or a paid subscription – the ROC serves curious consumers, medical professionals, and anyone else who is looking to better their life through cannabinoid therapies. The advice and suggestions are based on data, including the results from ROC’s own cannabis research registry.

Advocacy 135

Advocacy Education Events Epilepsy 135

Cannabis Law Report

SEPTEMBER 15, 2021

This deceptive marketing of unproven treatments raises significant public health concerns because patients and other consumers may use them instead of approved therapies to treat serious and even fatal diseases. The FDA has received adverse event reports involving delta-8 THC-containing products. brownies, gummies).

THC 105

THC Pets Events Hemp 105

Veriheal

JUNE 30, 2023

To start, participants reported that psilocybin had helped them process emotions tied to painful events in their past. Researchers say this emphasizes just how important it is that psilocybin therapy be done in a controlled setting with therapy and community-based after-care.

Clinical Trials 98

Clinical Trials Research and Development Therapy Policy 98

The Joint Blog

APRIL 17, 2020

This study summarizes potential adverse drug events related to THC when combined with other medications Medicinal Use of Marijuana Cannabis has been used widely across North America in various state or provincial medical marijuana programs. However, many interactions may be unavoidable, dose-limiting, or a barrier to THC-based therapy.

Events 48

Events THC Chronic Pain Conditions 48

The Joint Blog

MARCH 3, 2021

The study found “significant improvements were observed” following the initiation of cannabis therapy in most patients. The study concludes by stating that “The current study revealed the positive effects of MC [medical cannabis] therapy in some patients with FMS [ fibromyalgia syndrome] and resistance to conventional treatment.

Therapy 61

Therapy Hybrid Marijuana Research and Development 61

Cannabis Law Report

JUNE 16, 2021

Genetic Screening Platform Technology and Data to Strengthen Entheon’s Psychedelic-Assisted Protocols. Lobo brings a highly experienced and specialized team of technology experts in the fields of genetics, diagnostics, data and analytics, as well as a fully operational 5,000 sq. Vancouver, British Columbia–(Newsfile Corp.

Research and Development 105

Research and Development Data Conditions Events 105

Cannabis Law Report

JUNE 23, 2021

Sapphire Medical Clinics presented six abstracts focused on the latest research on cannabinoids based on data from the UK Medical Cannabis Registry during the 31st Annual International Cannabinoid Research Society Symposium on the Cannabinoids (ICRS2021). PROGRAMME.and.ABSTRACTS. Patient-reported outcomes. Improved quality of life.

Cannabinoids 45

Cannabinoids Data Chronic Pain Sleep 45

Veriheal

JUNE 21, 2022

It was then that the two of them began to fast-track what would turn out to be a successful event during the 2022 Aspen Gay Ski Week. This pop-up event was made possible by the partnership forged between Farnsworth, Cann, and Different Leaf. In the past when the panic attacks began I was prescribed Xanax to calm me down.

Therapy 95

Therapy Cannabis Events Tincture 95

TheAnswerPage

JANUARY 11, 2022

As a result, state medical marijuana rules and regulations have focused on the demands of the public without putting significant emphasis on the scientific data or the ability of the medical community to support and care for medical marijuana patients. Who monitors their health and the long-term effects of the marijuana therapy?

Patients 98

Patients Education Marijuana Therapy 98

LifeCannMD

MAY 27, 2025

Now, with 1.5mg of a balanced THC:CBD tincture twice daily, he’s giving presentations at work and actually enjoying social events again. Sleep: What the Sleep Studies Reveal A groundbreaking 2020 study from the University of New Mexico analyzed sleep data from over 5,000 medical marijuana patients.

Microdosing 52

Microdosing Research and Development Sleep Chronic Pain 52

Cannabis Law Report

AUGUST 3, 2021

Applied DNA undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, unless otherwise required by law. For Applied DNA: Investor contact: Sanjay M.

Clinical Trials 81

Clinical Trials Therapy Collective Research and Development 81

Cannabis Law Report

SEPTEMBER 2, 2021

Applied DNA undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, unless otherwise required by law. For Applied DNA: Investor contact: Sanjay M.

Clinical Trials 76

Clinical Trials Research and Development Therapy Collective 76

Cannabis Law Report

JANUARY 12, 2022

According to a recent report released by the Psychedelic Science Funders Collaborative, “Oregon’s psilocybin therapy program provides a high-quality model for psychedelic healing in a non-prescription context that could be replicated in other states.” ABOUT THE NATIONAL PSYCHEDELICS ASSOCIATION.

Research and Development 52

Research and Development Therapy Clinical Trials Safety 52

Puff Puff Post

MARCH 10, 2020

INM-755 is a CBN cream intended as a topical therapy to treat epidermolysis bullosa (EB) and potentially other dermatological diseases. About INM-755: INM-755 is a CBN cream intended as a topical therapy to treat epidermolysis bullosa (EB) and potentially other dermatological diseases.

Clinical Trials 84

Clinical Trials Pharmaceutical Research and Development Cannabinoids 84

Cannabis Law Report

SEPTEMBER 22, 2021

Data indicates potential of drug candidate to deliver an extremely potent therapeutic benefit at a very low non-toxic dose. New data will be presented at the 4th Annual International Cannabinoid-Derived Pharmaceuticals Summit in Boston. BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Watch how Supera-CBD works. “We

Pharmaceutical 40

Pharmaceutical Data CBD Clinical Trials 40

The Cannigma

OCTOBER 21, 2021

Another study of 11,232 ADHD patients found that those patients who also had a cannabis use disorder used less medication and behavioural therapy. Still there was only one adverse event – a period of extended rapid heart rate for one subject. The drug combination was well tolerated in most.

Blood Pressure 137

Blood Pressure Treatment Patients Cannabis 137

Cannabis Law Report

JUNE 7, 2021

1.526 were reduced as expected and consistent with other CDC-reported data on vaccine-induced antibody neutralization against these variants 1. The study showed neutralizing antibody titers against B.1.1.7 were not significantly impacted, while neutralizing antibody titers against P1 and B.1.526 Dr. James A.

Clinical Trials 49

Clinical Trials Research and Development Therapy Supply Chain 49

Cannabis Law Report

DECEMBER 9, 2021

These describe technology and infrastructure for the collection of precise, multimodal, multivalent data that can be processed via machine learning, artificial intelligence, signal processes, and other statistical methods to yield clinically meaningful output to satisfy the requirements of the IFU. NEW YORK , Dec. ” About MindMed.

Research and Development 52

Research and Development Clinical Trials Therapy Medicine 52

Cannabis Law Report

APRIL 8, 2022

as a non-profit organization to fulfill the need to broaden psychedelic research, therapy, and develop legal options for psychedelic medicine. In MAPS’ 36th year, we’ll learn if our second Phase 3 study of MDMA-assisted therapy for PTSD was successful. The FDA received MAPS’ protocol for a new study of MDMA-assisted therapy for PTSD.

Clinical Trials 52

Clinical Trials Therapy Research and Development DEA 52

Cannabis Law Report

JUNE 17, 2021

Silo Wellness is a publicly traded company on the CSE with a consumer-facing platform for the sale of functional mushroom products, psilocybin mushroom production in Jamaica, and the facilitation of psychedelic wellness retreats in both Jamaica and Oregon that incorporate a variety of psychedelic-augmented therapies.

Research and Development 75

Research and Development Therapy Access Media 75

SpeedWeed

MARCH 13, 2021

As a result, many PD patients now have legal access to cannabis as an alternative or complementary therapy. To learn more about the effectiveness of cannabis as a treatment for PD, a survey was sent to more than 7,600 people who had interacted with the Parkinson’s Foundation through events or the group’s helpline.

Patients 52

Patients Treatment Therapy Sleep 52

Cannabis Law Report

DECEMBER 9, 2021

Johnson recently reported his interim results at Microdose’s Psychedelic Medicine Business Event, from his current smoking cessation study, utilizing a single macro-dose of psilocybin. Preclinical data on numerous sets of Mydecine’s novel compounds are showing significant improvements compared to the first generation of drugs.

Clinical Trials 52

Clinical Trials Research and Development Therapy Treatment 52

The Joint Blog

AUGUST 30, 2020

Many seniors likely experimented first-hand with cannabis during their youth and are now returning to it as a potential therapy to mitigate many of the health-related symptoms that come with older age, including chronic pain. No significant associations were observed between the frequency of use and adverse events.

Marijuana 52

Marijuana Chronic Pain Events Therapy 52

Cannabis Law Report

AUGUST 23, 2021

He added that significant data is still needed to inform policy regarding use of consumer cannabis products. As a matter of a First Amendment right to free speech, vets should be able to talk to pet owners about CBD.

Pets 105

Pets Hemp CBD Food 105

Cannabis Law Report

JULY 28, 2021

The study was conducted by a respected contract research organization with deep expertise in preclinical oncology model development and drug testing and data corresponding to all studied cancer cell lines have now been reported to the Company. References: Yasuda, K., and Ohnishi, A.

Research and Development 105

Research and Development Clinical Trials Treatment Pharmaceutical 105

CannaMD

DECEMBER 9, 2020

The authors also list a range of additional conditions for which there are possible benefits of cannabis therapies, including opiate withdraw, dystonia, glaucoma, Alzheimer’s disease, anxiety and depression, anti-tumor effects, inflammatory bowel diseases, Parkinson’s disease, and sleep disorders. for men, 1.3%

Marijuana 111

Marijuana Research and Development Consumption Vaping 111

The Cannigma

OCTOBER 9, 2021

The common understanding is that every individual has a separate and different reaction to cannabinoid-based therapy, the same is true with how it might influence individual urinary symptoms. The effects of cannabis on micturition are complex with many factors at play.

Consumption 98

Consumption Cannabinoids Patients Cannabis 98

Cannabis Law Report

NOVEMBER 9, 2021

We find LinearDNA to be an excellent platform for CAR T-cell therapy development.”. These manufacturing complexities have likewise hindered research on CAR T-cell therapies. Dr. James A. About Applied DNA Sciences.

Clinical Trials 40

Clinical Trials Research and Development Therapy Supply Chain 40

Cannabis Law Report

JULY 2, 2021

Novel therapies and psychedelic treatments are rapidly gaining popularity across large swathes of North America as the awareness of mental health disorders and the revolutionary effects of psychedelics in their treatment become more mainstream. OTC: CLXPF), another Toronto-based firm engaged in the development of psychedelic therapies.

Research and Development 81

Research and Development Treatment Therapy Medicine 81

Cannabis Law Report

NOVEMBER 15, 2021

PCR-produced LinearDNA serves as a pure, fast, and flexible alternative to plasmid DNA (pDNA) in the manufacture of cell and gene therapies (CGTs) and nucleic acid vaccines. CRO orders typically provide a means to evaluate LinearDNA within a customer’s preclinical development program. News release. FDA website. January 15, 2019. 2021.08.006.

Research and Development 40

Research and Development Therapy Clinical Trials Supply Chain 40

Cannabis Law Report

OCTOBER 12, 2021

Applied DNA undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof or to reflect the occurrence of unanticipated events unless otherwise required by law. For Applied DNA: Investor Contact: Sanjay M.

Programs 40

Programs Clinical Trials Research and Development Therapy 40

Cannabis Law Report

NOVEMBER 9, 2021

Ketamine Wellness Centers (KWC) is the largest ketamine therapy provider in the United States with 10 clinic locations serving communities across eight states. Since 2011 KWC has been a trusted leader in bringing IV ketamine therapy into mainstream health care. Transaction Summary. About Ketamine Wellness Centers.

Treatment 52

Treatment Therapy Media Access 52

Cannabis Law Report

NOVEMBER 5, 2021

CLEARED4 captures, validates and matches user’s information to real-time health data including health surveys, temperature screening, integrated COVID-19 test results and vaccination status. Applied DNA has also established a COVID-19 diagnostic and testing offering that is grounded in the Company’s deep expertise in DNA.

Compliance 40

Compliance Compliance Research and Development Therapy 40

The Joint Blog

JUNE 28, 2021

Data shows that 9% of people who use marijuana will become addicted to it and 30% of people who use it might have some degree of marijuana use disorder. Lower levels of dopamine can lead people to lose interest in hobbies, previous passions, meetings or events, and other aspects of their normal life. Spending Most of the Time High.

Marijuana 52

Marijuana Events Treatment Therapy 52

Cannabis Law Report

SEPTEMBER 13, 2021

Positive data from this important study would significantly advance MYMD-1’s potential to become a blockbuster drug for inflammation and aging.”. Unlike other therapies, MYMD-1 is designed to selectively block TNF-? is the master regulator of inflammation, MYMD-1’s function as a TNF-? Chief Scientific Officer. 616–623.

Clinical Trials 40

Clinical Trials Pharmaceutical Research and Development Therapy 40

Cannabis Law Report

NOVEMBER 16, 2021

Phase 2 trial recruiting begins immediately; efficacy data expected by the end of the first quarter of 2022. Food and Drug Administration clearance of its Investigational New Drug (IND) application for the Phase 2 trial of MYMD-1 as a therapy for delaying aging and prolonging healthy lifespan. a driver of chronic inflammation.

Pharmaceutical 40

Pharmaceutical Clinical Trials Research and Development Therapy 40